Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 47 4 2009 08 15 275 278 EN Abdullah Bani-Hashem Department of Pediatric, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Farhad Heydarian Department of Pediatric, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Simin Hiradfar Department of Pathology, Dr. Sheikh Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hojatullah Ehteshammanesh Department of Pediatric, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2015 09 28 Asparaginase is one of the most important agents in the treatment of ALL. However, it has some side effects including dislipidemia, hyperglycemia, coagulopathy and hepatotoxicity. We studied its side ef-fects on our patients. The effects of L-asparaginase were assessed on 25 new ALL patients (case group) and 25 patients with known ALL who had completed their treatment before. Sixty two percent of cases were male and remainder was female. The mean age of patients was 7.2 ± 3.8 years. In our patients, there was a rise in triglycerides (TG) was seen following L- asparaginase administration (P = 0.02). Also, PT prolongation (P = 0.02) and hypoalbominemia (P = 0.002) were detected which could PT prolongation and hypoalbuminemia may be seen with L-asparaginase therapy that can be prevented with transfusion of FFP. Hypertriglyceridemia is often asymptomatic with no need for therapy. https://acta.tums.ac.ir/index.php/acta/article/view/3590 https://acta.tums.ac.ir/index.php/acta/article/download/3590/3566